Abstract:Background: Effective targeting therapies for common chronic liver disease nonalcoholic steatohepatitis (NASH) are in urgent need. MicroRNA-targeted therapeutics would be potentially an effective treatment strategy of hepatic diseases. Here we investigated the functional role of miR-221/222 and the therapeutic effects of antimiRs-221/222 in NASH mouse models. Methods: We generated the miR-221/222flox/flox mice on a C57BL/6 J background and the hepatic miR-221/222 knockout (miR-221/222-LKO) mice. The mice were challenged with the methionine and choline deficient diet (MCDD) or chronic carbon tetrachloride (CCl4) treatment to generate experimental steatohepatitis models. Adenovirus-mediated re-expression of miR-221/222 was performed on the MCDD-fed miR-221/222-LKO mice. The MCDD and control diet-fed mice were treated with locked nucleic acid (LNA)-based antimiRs of miR-221/222 to evaluate the therapeutic effects. Histological analysis, RNA-seq, quantitative PCR and Western blot of liver tissues were carried out to study the hepatic lipid accumulation, inflammation and collagen deposition in mouse models. Findings: Hepatic deletion of miR-221/222 resulted in significant reduction of liver fibrosis, lipid deposition and inflammatory infiltration in the MCDD-fed and CCl4-treated mouse models. The hepatic steatosis and fibrosis were dramatically aggravated by miR-221/222 re-expression in MCDD-fed miR-221/222-LKO mice. AntimiRs of miR-221/222 could effectively reduce the MCDD-mediated hepatic steatosis and fibrosis. Systematically mechanistic study revealed that hepatic miR-221/222 controlled the expression of target gene Timp3 and promoted the progression of NASH. Interpretation: Our findings demonstrate that miR-221/222 are crucial for the regulation of lipid metabolism, inflammation and fibrosis in the liver. LNA-antimiRs targeted miR-221/222 could reduce steatohepatitis with prominent antifibrotic effect in NASH mice. Fund: This work is supported by the Natural Science Foundation of China (81530020, 81390352 to Dr. Ning and 81522032 to Dr. Cao and 81670793 to Dr. Jiang); National Key Research and Development Program (No. 2016YFC0905001 and 2017YFC0909703 to Dr. Cao); the Shanghai Rising-Star Program (15QA1402900 to Dr. Cao); Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant (20171905 to Dr. Jiang). Keywords: miR-221/222, NASH, Liver fibrosis, miRNA-targeted therapeutics

miR-21: A therapeutic target for delaying severe liver disease and hepatocellular carcinoma in high-fat-diet-fed mice

Abstract 5689: miR-21: A therapeutic target that delays severe liver disease and hepatocellular carcinoma under high-fat-diet conditions

Uric Acid Induced Hepatocytes Lipid Accumulation Through Regulation of Mir-149-5p/fgf21 Axis

MicroRNA-101 Suppresses Liver Fibrosis by Downregulating PI3K/Akt/mTOR Signaling Pathway

Aberrant Hepatic Microrna Expression in Nonalcoholic Fatty Liver Disease

MicroRNA-21 Contributes to Liver Regeneration by Targeting PTEN

MicroRNA-21 is a potential link between non-alcoholic fatty liver disease and hepatocellular carcinoma via modulation of the HBP1-p53-Srebp1c pathway

Mir-149 Controls Non-Alcoholic Fatty Liver by Targeting Fgf-21

Anti–miR-21 Suppresses Hepatocellular Carcinoma Growth Via Broad Transcriptional Network Deregulation

Role and Mechanisms of Action of Microrna‑21 As Regards the Regulation of the WNT/β‑catenin Signaling Pathway in the Pathogenesis of Non‑alcoholic Fatty Liver Disease.

Critical Role of microRNA-21 in the Pathogenesis of Liver Diseases

Mutation of Mir-21 Targets Endogenous Lipoprotein Receptor-Related Protein 6 and Nonalcoholic Fatty Liver Disease.

The Critical Role of microRNA-21 in Non-alcoholic Fatty Liver Disease Pathogenesis

MicroRNA-451 and Genistein Ameliorate Nonalcoholic Steatohepatitis in Mice.

Targeting hepatic miR-221/222 for therapeutic intervention of nonalcoholic steatohepatitis in miceResearch in context

Knockout of microRNA-21 attenuates alcoholic hepatitis through the VHL/NF-κB signaling pathway in hepatic stellate cells.

MicroRNA-21 Suppresses PTEN and Hsulf-1 Expression and Promotes Hepatocellular Carcinoma Progression Through AKT/ERK Pathways.

Targeting hepatic miR-221/222 for therapeutic intervention of nonalcoholic steatohepatitis in mice.

Targeting Hepatic Mir-221/222 for Therapeutic Intervention of Nonalcoholic Steatohepatitis in Mice

MiR-182-5p Is Upregulated in Hepatic Tissues from a Diet-Induced NAFLD/NASH/HCC C57BL/6J Mouse Model and Modulates Cyld and Foxo1 Expression

Investigation of the clinical significance and molecular mechanism of miR-21-5p in hepatocellular carcinoma: A systematic review based on 24 studies and bioinformatics investigation.